Renaissance Technologies
SABS icon

Renaissance Technologies’s SAB Biotherapeutics SABS Stock Holding History

Renaissance Technologies’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$139K Buy
+43,800
New +$159K ﹤0.01% 2970
2025
Q4 		– Sell
-80,840
Closed -$162K – 3686
2025
Q3 		$162K Buy
80,840
+69,810
+633% +$158K ﹤0.01% 3175
2025
Q2 		$19.4K Buy
11,030
+1,000
+10% +$1.66K ﹤0.01% 3472
2025
Q1 		$13.6K Buy
+10,030
New +$23K ﹤0.01% 3377
2024
Q1 		– Sell
-6,310
Closed -$43K – 4016
2023
Q4 		$43K Buy
6,310
+500
+9% +$4.19K ﹤0.01% 3478
2023
Q3 		$37K Buy
5,810
+370
+7% +$2.72K ﹤0.01% 3443
2023
Q2 		$45K Buy
+5,440
New +$44.6K ﹤0.01% 3637

Other funds holding SABS

Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Polymer Capital Management (HK)
Polymer Capital Management (HK) Hong Kong $1.06B AUM 138.97% 1-Year Est. Return
HB Wealth Management
HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $96.6B AUM 22.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Renaissance Technologies's SABS Position: Q3 2026 in Review

Renaissance Technologies opened a new position in SAB Biotherapeutics (SABS) in Q3 2026: 43,800 shares worth $139K. The stake represents ﹤0.01% of the portfolio and ranks #2970 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in SABS as recently as Q3 2025.

Renaissance Technologies first reported a position in SABS in Q2 2023 and has held it in 7 quarters since. The position peaked at $162K in Q3 2025. 45 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Renaissance Technologies held 43,800 shares of SAB Biotherapeutics worth $139K as of Q3 2026.
  • SAB Biotherapeutics was a new Renaissance Technologies position in Q3 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q3 2026, its #2970 holding.
  • Renaissance Technologies first reported a position in SAB Biotherapeutics in Q2 2023 and has held it in 7 quarters since.
  • Renaissance Technologies's SAB Biotherapeutics position peaked at $162K in Q3 2025.
  • 45 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.